- Conditions
- Heart Failure
- Interventions
- Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
- Drug · Device
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure (HF), Ventricular Dysfunction, Left
- Interventions
- AdreView (Iobenguane I 123 Injection)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Neuroendocrine Tumors
- Interventions
- 3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan, Planar scintigraphy scan, Single photon emission computed tomography/computed tomography scan
- Drug · Diagnostic Test
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Stress Induced Cardiomyopathy
- Interventions
- I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Neuroblastoma
- Interventions
- Iobenguane I 123 Injection
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Pheochromocytoma, Neuroblastoma
- Interventions
- 123I-mIBG (meta-iodobenzylguanidine)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- Not listed
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Ventricular Tachycardia, Arrhythmia
- Interventions
- 123I-metaiodobenzylguanidine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland